Loss-of-function mutations in the cell-cycle control gene CDKN2A impact on glucose homeostasis in humans

Diabetes

Volumn 65, Issue 2, 2016, Pages 527-533

  Pal, Aparna ^a   Potjer, Thomas P ^b   Thomsen, Soren K ^a   Ng, Hui Jin ^a   Barrett, Amy ^a   Scharfmann, Raphael ^c   James, Tim J ^d   Bishop, D Timothy ^e   Karpe, Fredrik ^a,f   Godsland, Ian F ^g   Vasen, Hans F A ^b   Newton Bishop, Julia ^e   Pijl, Hanno ^b   McCarthy, Mark I ^a,f,h   Gloyn, Anna L ^a,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUT COCHIN   (France)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLUCOSE; INSULIN; MESSENGER RNA; SMALL INTERFERING RNA; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CDKN2A GENE; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEPATIC CLEARANCE; HUMAN; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LOSS OF FUNCTION MUTATION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHENOTYPE; PRIORITY JOURNAL; ADOLESCENT; AGED; BILIARY EXCRETION; CELL LINE; GENE SILENCING; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN RESISTANCE; METABOLISM; MUTATION; PHYSIOLOGY; SECRETION (PROCESS); STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CELL LINE; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENES, P16; GLUCOSE TOLERANCE TEST; HEPATOBILIARY ELIMINATION; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84962476739     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0602     Document Type: Article

References (26)

1. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589
2. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-990
3. Grarup N, Rose CS, Andersson EA, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 2007; 56: 3105-3111
4. Dimas AS, Lagou V, Barker A, et al.; MAGIC Investigators. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 2014; 63: 2158-2171
5. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440
6. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707
8. Weber HO, Samuel T, Rauch P, Funk JO. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002; 21: 3207-3212
9. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006; 443: 453-457
10. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999; 22: 44-52
11. Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature 2014; 510: 547-551
12. Bantubungi K, Hannou SA, Caron-Houde S, et al. Cdkn2a/p16Ink4a regulates fasting-induced hepatic gluconeogenesis through the PKA-CREB-PGC1α pathway. Diabetes 2014; 63: 3199-3209
13. Martín J, Hunt SL, Dubus P, et al. Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 2003; 22: 5261-5269
14. Fiaschi-Taesch N, Bigatel TA, Sicari B, et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes 2009; 58: 882-893
15. Fiaschi-Taesch NM, Salim F, Kleinberger J, et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 2010; 59: 1926-1936
16. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258: 1148-1152
17. Goldstein AM Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23: 630
18. Godsland IF, Agbaje OF, Hovorka R. Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. Am J Physiol Endocrinol Metab 2006; 291:E167-E174
19. Ravassard P, Hazhouz Y, Pechberty S, et al. A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 2011; 121: 3589-3597
20. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975; 55: 1278-1283
21. McKenzie HA, Fung C, Becker TM, et al. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat 2010; 31: 692-701
22. Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998; 110: 932-938
23. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31(Suppl. 2): S262-S268
24. Hannou SA, Wouters K, Paumelle R, Staels B. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? Trends Endocrinol Metab 2015; 26: 176-184
25. Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 2014; 46: 136-143
26. Fadista J, Vikman P, Laakso EO, et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc Natl Acad Sci U S A 2014; 111: 13924-13929